[1] Ikonomou L, Freishtat RJ, Wagner DE, Panoskaltsis-Mortari A, Weiss DJ. The Global Emergence of Unregulated Stem Cell Treatments for Respiratory Diseases Professional Societies Need to Act. Ann Am Thorac Soc 2016;13(8):1205-1207.

[2] Cuende N, Rasko JEJ, Koh MBC, Dominici M, Ikonomou L. Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy 2018;20(11):1401-1413.

[3] Wagner DE, Turner L, Panoskaltsis-Mortari A, Weiss DJ, Ikonomou L. Co-opting of ClinicalTrials.gov by patient-funded studies. Lancet Resp Med 2018;6(8):579-581.

[4] Weiss DJ, Turner L, Levine AD, Ikonomou L. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions. Cytotherapy 2018;20(2):165-168.

[5] Ikonomou L, Levine AD, Hematti P, Levine BL. Cell Banking for Cell and Gene Therapy-Regulatory, Ethical, and Scientific Considerations. Bioprocess Int 2021;19((6)i):10-13.

[6] Turner L, Munsie M, Levine AD, Ikonomou L. Ethical issues and public communication in the development of cell-based treatments for COVID-19: Lessons from the pandemic. Stem Cell Rep 2021;16(11):2567-2576.